Pharma Update

Ophthalmology pipeline gaining momentum Expanding into new disease areas with satralizumab initiating Ph III in TED Roche Phasel Phase II Phase III Launched RG6351 NME Retinal disease RG6179 anti-IL-6 DME RG7716 Vabysmo⭑ BRVO RG7716 Vabysmo nAMD RG6209 NME Retinal disease RG6501 OpRegen¹ GA RG7716 Vabysmo⭑ RG7716 CRVO Vabysmo DME NME RG7921 RVO WWW.000. M ASO factor B² Susvimo Susvimo RG6299 RG6321 RG6321 > > > GA DME nAMD RG6120 Zifibancimig (VEGF-Ang2 DutaFab) nAMD Susvimo RG6321 DR nAMD RVO anti-IL-6 DME/UME RG6179 UME GA Retinal disease FDA approval RG6168 satralizumab TED DR TED Filed in US & EU Upcoming readouts: Data expected for ASO factor B in GA in 2024 Data expected for anti-IL-6 in DME in 2024 and UME in 2025 Antibody DutaFab PDS Wi Antisense oligonucleotide Stem cell therapy 1 In collaboration with Lineage Cell Therapeutics (LCTX); 2 In collaboration with lonis; nAMD-neovascular age-related macular degeneration; DME-diabetic macular edema; UME-Uveitic macular edema; DR-diabetic retinopathy; BRVO-branch retinal vein occlusion; CRVO-central retinal vein occlusion; GA-geographic atrophy; DutaFabs-dual targeting fragment antigen-binding; VEGF-vascular endothelial growth factor; Ang- 2-angiopoietin-2; IL-6=inter-leukin-6; TED-Thyroid eye disease; PDS-Port delivery system; ASO=Antisense oligonucleotide 123

View entire presentation